Marshall–Olkin gamma–Weibull distribution with applications

Abstract

A Marshall–Olkin variant of the Provost type gamma–Weibull probability distribution is being introduced in this paper. Some of its statistical functions and numerical characteristics among others characteristics function, moment generalizing function, central moments of real order are derived in the computational series expansion form and various illustrative special cases are discussed. This density function is utilized to model two real data sets. The new distribution provides a better fit than related distributions as measured by the Anderson–Darling and Cramér–von Mises statistics. The proposed distribution could find applications for instance in the physical and biological sciences, hydrology, medicine, meteorology, engineering, etc.     

Estimation of discrete survival function for error‐prone diagnostic tests

The product limit or Kaplan‐Meier (KM) estimator is commonly used to estimate the survival function in the presence of incomplete time to event. Application of this method assumes inherently that the occurrence of an event is known with certainty. However, the clinical diagnosis of an event is often subject to misclassification due to assay error or adjudication error, by which the event is assessed with some uncertainty. In the presence of such errors, the true distribution of the time to first event would not be estimated accurately using the KM method. We develop a method to estimate the true survival distribution by incorporating negative predictive values and positive predictive values, into a KM‐like method of estimation. This allows us to quantify the bias in the KM survival estimates due to the presence of misclassified events in the observed data. We present an unbiased estimator of the true survival function and its variance. Asymptotic properties of the proposed estimators are provided, and these properties are examined through simulations. We demonstrate our methods using data from the Viral Resistance to Antiviral Therapy of Hepatitis C study.     

Joint modeling of longitudinal continuous,longitudinal ordinal,and time-to-event outcomes

Lifetime Data Analysis - In this paper, we propose an innovative method for jointly analyzing survival data and longitudinally measured continuous and ordinal data. We use a random effects...     

Comparison of treatment regimes with adjustment for auxiliary variables

Treatment regimes are algorithms for assigning treatments to patients with complex diseases, where treatment consists of more than one episode of therapy, potentially with different dosages of the same agent or different agents. Sequentially randomized clinical trials are usually designed to evaluate and compare the effect of different treatment regimes. In such designs, eligible patients are first randomly assigned to receive one of the initial treatments. Patients meeting some criteria (e.g. no progressive disease) are then randomized to receive one of the maintenance treatments. Usually, the procedure continues until all treatment options are exhausted. Such multistage treatment assignment results in treatment regimes consisting of initial treatments, intermediate responses and second-stage treatments. However, methods for efficient analysis of sequentially randomized trials have only been developed very recently. As a result, earlier clinical trials reported results based only on the comparison of stage-specific treatments. In this article, we propose a model that applies to comparisons of any combination of any number of treatment regimes regardless of the number of stages of treatment adjusted for auxiliary variables. Contrasts of treatment regimes are tested using the Wald chi-square method. Both the model and Wald chi-square tests of contrasts are illustrated through a simulation study and an application to a high-risk neuroblastoma study to complement the earlier results reported on this study.     

Inference for two-stage adaptive treatment strategies using mixture distributions

Summary.  Treatment of complex diseases such as cancer, leukaemia, acquired immune deficiency syndrome and depression usually follows complex treatment regimes consisting of time varying multiple courses of the same or different treatments. The goal is to achieve the largest overall benefit defined by a common end point such as survival. Adaptive treatment strategy refers to a sequence of treatments that are applied at different stages of therapy based on the individual's history of covariates and intermediate responses to the earlier treatments. However, in many cases treatment assignment depends only on intermediate response and prior treatments. Clinical trials are often designed to compare two or more adaptive treatment strategies. A common approach that is used in these trials is sequential randomization. Patients are randomized on entry into available first-stage treatments and then on the basis of the response to the initial treatments are randomized to second-stage treatments, and so on. The analysis often ignores this feature of randomization and frequently conducts separate analysis for each stage. Recent literature suggested several semiparametric and Bayesian methods for inference related to adaptive treatment strategies from sequentially randomized trials. We develop a parametric approach using mixture distributions to model the survival times under different adaptive treatment strategies. We show that the estimators proposed are asymptotically unbiased and can be easily implemented by using existing routines in statistical software packages.     

Incorporating diagnostic accuracy into the estimation of discrete survival function

Empirical distribution function (EDF) is a commonly used estimator of population cumulative distribution function. Survival function is estimated as the complement of EDF. However, clinical diagnosis of an event is often subjected to misclassification, by which the outcome is given with some uncertainty. In the presence of such errors, the true distribution of the time to first event is unknown. We develop a method to estimate the true survival distribution by incorporating negative predictive values and positive predictive values of the prediction process into a product-limit style construction. This will allow us to quantify the bias of the EDF estimates due to the presence of misclassified events in the observed data. We present an unbiased estimator of the true survival rates and its variance. Asymptotic properties of the proposed estimators are provided and these properties are examined through simulations. We evaluate our methods using data from the VIRAHEP-C study.     

Estimation of survival quantiles in two-stage randomization designs

In two-stage randomization designs, patients are randomized to one or more available therapies upon entry into the study. Depending on the response to the initial treatment (such as complete remission or shrinkage of tumor), patients are then randomized to receive maintenance treatments to maintain the response or salvage treatment to induce response. One goal of such trials is to compare the combinations of initial and maintenance or salvage therapies in the form of treatment strategies. In cases where the endpoint is defined as overall survival, Lunceford et al. [2002. Estimation of survival distributions of treatment policies in two-stage and randomization designs in clinical trials. Biometrics 58, 48–57] used mean survival time and pointwise survival probability to compare treatment strategies. But, mean survival time or survival probability at a specific time may not be a good summary representative of the overall distribution when the data are skewed or contain influential tail observations. In this article, we propose consistent and asymptotic normal estimators for percentiles of survival curves under various treatment strategies and demonstrate the use of percentiles for comparing treatment strategies. Small sample properties of these estimators are investigated using simulation. We demonstrate our methods by applying them to a leukemia clinical trial data set that motivated this research.     

Prognostic accuracy for predicting ordinal competing risk outcomes using ROC surfaces

Lifetime Data Analysis - Many medical conditions are marked by a sequence of events in association with continuous changes in biomarkers. Few works have evaluated the overall accuracy of a...